Senseonics, Rimidi Team Up for Remote Diabetes Monitoring

Senseonics has begun a strategic partnership with Rimidi, a clinical management platform to optimize clinical workflows, enhance patient experience, and reach quality objectives for chronic disease management.
 
The duo will collaborate on development of Senseonics’ Eversense implantable glucose monitor (CGM) remote patient monitoring (RPM) program for use by healthcare providers. Eversense glucose data will be integrated into Rimidi’s clinical management platform.
 
Rimidi’s platform aligns with Medicare’s reimbursable RPM telehealth program. It integrates within existing electronic health record (EHR) systems to support quality improvement initiatives. This aims to drive workflow optimization, increase patient engagement, and offer clinical decision support.
 
The Eversense CGM + RPM solution will securely push patient data to the most widely used EHR systems so healthcare providers can have direct access. More visibility on glucose trends, high/low event frequency, and time-in-range statistics will allow providers to proactively engage patients. That way, lifestyle and therapy optimization guidance can be provided for better diabetes management, lower healthcare costs, and better outcomes, according to the companies.
 
“We are excited to combine our clinical management platform with Senseonics’ technology. Our platform and its capabilities were designed to leverage the data from medical devices like Eversense CGM to streamline and improve chronic disease management,” said Rimidi CEO Lucienne Ide, MD, P.hD. “81% of patients with type 2 diabetes do not meet their HbA1c, blood pressure and cholesterol goals, and this partnership represents an exciting opportunity to assist providers in driving improved glucose outcomes for this population.”
 
Senseonics and commercial partner Ascensia Diabetes Care plan to make the Eversense CGM+RPM solution available to select population-based health systems in Q3 2024. A planned expansion to all healthcare providers and Eversense users will follow.
 
“The Eversense RPM Program is the next step in our roadmap to combine long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution. Eversense RPM will arm providers with powerful data to optimize care in between office visits where 99% of diabetes management takes place,” said Tim Goodnow, Ph.D., president and CEO of Senseonics. “Rimidi’s best-in-class platform will seamlessly integrate Eversense data. Combined with expert diabetes nurse counselors, proprietary decision support protocols, and fully compliant RPM reimbursement infrastructure, our Eversense CGM+RPM solution is intended to further differentiate Eversense from other CGM manufacturers, reaching beyond a stand-alone device and putting a comprehensive solution into the hands of health care systems, providers, and patients. Aligned with Medicare’s diabetes population management initiatives, we are proud to be at the forefront of providing the next evolution of innovation in diabetes with the goal to give healthcare professionals the confidence of knowing patients have support outside of their office and patients the confidence of achieving healthy outcomes. We look forward to providing Ascensia, our commercial partner, with this exciting program, offering further reason for providers and patients to choose Eversense.”
 
Last month, the Eversense implantable CGM was granted integrated CGM (iCGM) designation by the U.S. Food and Drug Administration (FDA). It’s the first fully implantable device in the category.